Pebble Biotechnology Laboratories

Pebble Biotechnology Laboratories is a Cambridge-based service provider founded in 2016, with a team claiming 25 years of collective experience in de-risking and advancing external medical innovations. The company's core business is taking client-owned therapies, devices, and diagnostic techniques, rigorously testing them, and generating the clinical evidence required for regulatory approval, clinical trial advancement, and adoption into standard care. It is highly selective, focusing only on projects with the potential to change clinical practice, and its case studies cite impact on hundreds of thousands of patients annually. Pebble positions itself as a critical, evidence-focused partner for innovators bridging the gap between lab bench and patient bedside.

Integrated translational science service methodology for testing, refining, and generating clinical evidence for external medical innovations (therapies, devices, diagnostics).

Competes with large, full-service Contract Research Organizations (CROs) and niche consulting firms specializing in translational medicine. Differentiation is based on a selective, high-touch model focused on practice-changing outcomes rather than volume. Must also contend with in-house capabilities at larger biopharma companies.